- Home
- XENE vs ACAD Comparison
XENE vs ACAD Comparison
Compare XENE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- ACAD
- Stock Information
- Founded
- XENE 1996
- ACAD 1993
- Country
- XENE Canada
- ACAD United States
- Employees
- XENE N/A
- ACAD N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- ACAD Health Care
- Exchange
- XENE Nasdaq
- ACAD Nasdaq
- Market Cap
- XENE 3.3B
- ACAD 2.9B
- IPO Year
- XENE 2014
- ACAD 2004
- Fundamental
- Price
- XENE $41.08
- ACAD $17.39
- Analyst Decision
- XENE Strong Buy
- ACAD Buy
- Analyst Count
- XENE 9
- ACAD 19
- Target Price
- XENE $56.67
- ACAD $26.44
- AVG Volume (30 Days)
- XENE 361.3K
- ACAD 1.5M
- Earning Date
- XENE 11-12-2024
- ACAD 11-06-2024
- Dividend Yield
- XENE N/A
- ACAD N/A
- EPS Growth
- XENE N/A
- ACAD N/A
- EPS
- XENE N/A
- ACAD 0.78
- Revenue
- XENE N/A
- ACAD $929,236,000.00
- Revenue This Year
- XENE N/A
- ACAD $37.34
- Revenue Next Year
- XENE $1,599.99
- ACAD $7.25
- P/E Ratio
- XENE N/A
- ACAD $22.41
- Revenue Growth
- XENE N/A
- ACAD 47.06
- 52 Week Low
- XENE $35.53
- ACAD $14.15
- 52 Week High
- XENE $50.99
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- XENE 48.67
- ACAD 54.79
- Support Level
- XENE $38.95
- ACAD $16.78
- Resistance Level
- XENE $43.20
- ACAD $17.60
- Average True Range (ATR)
- XENE 1.51
- ACAD 0.68
- MACD
- XENE -0.11
- ACAD -0.03
- Stochastic Oscillator
- XENE 51.27
- ACAD 45.21
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.